Drug Profile
MAG 200
Alternative Names: MAG200Latest Information Update: 27 May 2021
Price :
$50
*
At a glance
- Originator Magellan Biologicals
- Class Cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Osteoarthritis
Most Recent Events
- 27 May 2021 Magellan Biologicals has patent protection related to clinical treatment of stem cells (Magellan Biologicals, May 2021)
- 27 May 2021 Safety data from phase I trial in Osteoarthritis released by Magellan Biotech
- 27 May 2021 Magellan Biologicals completes phase I trial in Osteoarthritis in Australia (Intra-articular) prior to May 2021 (ACTRN12617001095358) (Magellan Biologicals, May 2021)